Chemicon International, Inc. Licenses Its Patented Amplifluor Technology for Cancer Diagnostics to Oncomethylome Sciences S.A.
DNA methylation is one of the primary biological mechanisms that determine gene expression. Thus, DNA methylation is an essential control mechanism for the normal development and cellular functioning of organisms. Abnormal DNA methylation, or hyper-methylation of DNA, incorrectly switches off critical genes, such as tumor suppressor genes or DNA repair genes, allowing cancers to develop and progress. DNA methylation patterns act as specific markers for disease and measuring the differences in DNA methylation patterns between healthy and diseased states provides a reliable and sensitive method for identifying disease and disease progression.
"This licensing agreement with OncoMethylome Sciences underscores Amplifluor's(R) broad reaching capabilities for DNA/RNA based detection applications in both the research and diagnostic arenas," said Jeffrey D. Linton, President of Chemicon. "In addition, OMS and Chemicon are dedicated, through our further collaborative efforts, to continue to provide innovative, enabling tools and technologies to accelerate and advance discoveries in the field of methylation and cancer research."
"We are very pleased to have gained access to Chemicon's powerful Amplifluor(R) detection technology for our cancer diagnostic assays," said Herman Spolders, CEO of OncoMethylome Sciences. "We believe that coupling Amplifluor(R) with our patented methylation technology will accelerate our development of leading edge diagnostic assays for cancer prognosis, diagnosis and screening as well as individualized patient treatment."
The Amplifluor(R) fluorescent detection system is a powerful and flexible platform that can be utilized for a variety of nucleic acid amplification techniques. Amplifluor(R) can be incorporated into a wide array of analytical applications appropriate to HTS in drug discovery with other applications in genomics, clinical diagnostics, forensics, biothreat and food testing. In addition, Amplifluor(R) has been successfully used with strand displacement amplification, nucleic acid sequence-based amplification, and cascade rolling-circle amplification techniques. The Amplifluor(R) technology leverages the incorporation of fluorescently labeled hairpin primers into an amplicon rather than hybridization of a fluorescently labeled probe to a target. Amplifluor(R) can be used both for quantitative analysis as well as qualitative identification providing a universal tool for genetic analysis.
Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA.
For more information, please visit our website: www.chemicon.com.
OncoMethylome Sciences S.A. is a leader in the research, design and validation of molecular gene methylation tests to (1) detect cancer at an early stage of the disease and at a higher level of accuracy than currently available tests; (2) determine the aggressiveness profile of a patient's cancer; and (3) predict and monitor response to cancer therapy for optimal and more individualized treatment decisions. The OncoMethylome Sciences offices are located in the Research Triangle Park area of Durham, NC, USA and in Belgium and the Netherlands.
For more information, visit the website of the Company at www.oncomethylome.com.
Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.
For more information, please visit our website: www.serologicals.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. These risks and uncertainties include, without limitation, our ability to provide innovative, enabling tools and technologies to accelerate and advance discoveries in the field of methylation and cancer research. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release.
Serologicals is a registered trademark of Serologicals Royalty Company.
Amplifluor is a registered trademark of Chemicon International, Inc.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 30, 2005|
|Previous Article:||ARKOON and 6WIND on a Winning Strategy to Address Large Enterprise Networks.|
|Next Article:||Marlton Technologies, Inc. Reports 2004 Results.|